Alzamend Neuro secures $7.5 million in initial tranche of Convertible Preferred Stock from Ault Lending as part of a $25 million agreement to support development efforts.
Amount Raised
$7.5 Million
Round Type
Series D
AtlantaBiotechnologyHealth CareScience And EngineeringInvestors
Description
Alzamend Neuro has announced the initial closing of a Securities Purchase Agreement with Ault Lending. The agreement allows Ault Lending to purchase up to $25 million of the company's Series D Convertible Preferred Stock. Ault Lending has closed on the initial tranche of $7.5 million. The proceeds will be used for general working capital and corporate purposes.
Quick answer
Alzamend Neuro raised $7.5 Million in a Series D round, dated August 4, 2026. Investors: Purchaser and Ault Lending, LLC. Alzamend Neuro is based in Atlanta, Georgia, United States.
- How much did Alzamend Neuro raise?
- Alzamend Neuro raised $7.5 Million in a Series D round on August 4, 2026.
- Who invested in Alzamend Neuro?
- Purchaser and Ault Lending, LLC are named as investors in this round.
- What does Alzamend Neuro do?
- Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress..
- Where is Alzamend Neuro based and how big is it?
- Alzamend Neuro is based in Atlanta, Georgia, United States. Fundz records about 7 employees.
- Who are the decision-makers at Alzamend Neuro?
- Fundz holds 1 contact at Alzamend Neuro, including the Deputy General Counsel and Vice President of Legal Affairs. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Alzamend Neuro that raised within 45 days of this round, from Fundz verified event records.
- Saol Therapeutics raised $115M on September 15, 2026.
- IMPLICITY raised $41M on September 9, 2026.
- ImpriMed raised $10M (Series A) on September 18, 2026.
- Big Picture Bio raised $2M (Pre-Seed) on September 18, 2026.
- Phosphoenix raised $1.5M (Seed) on September 18, 2026.
- Navigator Medicines raised $10M on September 18, 2026.
Who to call at Alzamend Neuro, and when
A new round usually means Alzamend Neuro is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alzamend Neuro raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alzamend Neuro, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alzamend Neuro. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alzamend Neuro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Alzamend Neuro raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.